2019-09-04 13:54 ET - News Release
Also News Release (C-DOSE) Rapid Dose Therapeutics Corp
Mr. Edgar Montero of Chemesis reports
CHEMESIS INTERNATIONAL INC. PROVIDES UPDATE ON RAPID DOSE
Chemesis International Inc.'s subsidiary, Natural Ventures, has completed the installation, permitting and testing phase of its QuickStrip oral thin strip production equipment. The Company has completed the previously announced commercialization strategy, and has begun accepting orders for QuickStrip for immediate distribution across Puerto Rico and the United States.
Since receiving Gold Vendor Status from Rapid Dose Therapeutics Corp. ("RDT") ( CSE: DOSE ) Chemesis has continued to work diligently to ensure the QuickStrip go to market strategy is done effectively and efficiently. The Company expects to see a consistent increase in revenue as consumers move to a more Quick, Convenient, Precise, and Discrete{&#A A ; ™} method of consumption.
"Our partnership with RDT brings an incredible amount of potential growth for Chemesis," said Chief Executive Officer of Chemesis, Edgar Montero. "The partnership gives Chemesis access to a large market of consumers that are looking for alternatives that provide a No Smoke, No Smell, No Stigma administration of THC or CBD." On Behalf of The Board of Directors
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico and Colombia. The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities.
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet{&#A A ; ™} choices to consumers.